



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-1736-D)

In the Application of:

Hom, et al.

Serial No. 09/816,876

Filed: March 23, 2001

For: Compounds to Treat Alzheimer's Disease

)
)
) Examiner: T. Criares
)
) Art Unit: 1617
)
) Confirmation No.: 6062
)
)

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:


In regard to the above identified application,

1. We are transmitting herewith the attached:
 - a) Response to the Office Action Mailed April 22, 2004; and
 - b) Return Receipt Postcard.
2. With respect to fees:
 - a) No fee is due.
 - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on May 18, 2004.

Respectfully submitted,

Dated: May 18, 2004


Bradley W. Crawford
Registration No. 50,494



1617
IFW

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450,

on May 18, 2004 (Date of Deposit).

5/18/04 Monica Eubanks
Date Name

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Attorney Docket No. 01-1736-D)

In re Application of:)	
Hom et al.)	Before the Examiner:
)	T. Criares
Serial No.: 09/816,876)	
)	Art Unit: 1617
Filed: March 23, 2001)	
)	
For: Compounds to Treat)	Confirmation No.: 6062
Alzheimer's Disease)	

RESPONSE TO THE OFFICE ACTION


MAILED APRIL 22, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Responsive to the Office Action mailed April 22, 2004, Applicants elect the claims of Group V, i.e., claims 49-59, for prosecution. Further, Applicants elect the species of Example 53 on page 174. The compound of that example is named in the specification as 4-(anti)-([6-(3,5-Difluoro-phenyl)-5-(S)-(3-dipropylcarbamoyl-benzoylamino)-4-(S)-hydroxyl-2-(R)-isobutyl-

hexanoylamino]-methyl)-cyclohexanecarboxylic acid: and can be represented by the following structure:




Applicants note that the prior response to the restriction requirement contained an error in the structure. The above structure is correct, and is within the scope of formula XII.

Applicants urge the Examiner to contact the Applicants' undersigned representative at (312) 913-2114 if it is believed that a discussion would expedite prosecution of this application.

Respectfully submitted,

Dated: May 18, 2004

By:


Bradley W. Crawford
Reg. No. 50,494

McDonnell Boehnen
Hulbert & Berghoff
300 South Wacker Drive
Chicago, Illinois 60606
(312) 913-0001